Author | Marco Meglio


Ozanimod Shows Long-Term Safety, Efficacy in Open-Label Extension

September 18, 2020

Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.

Sumifilam Improves Multiple Alzheimer Disease Biomarkers in Phase 2b Study

September 17, 2020

The results point to the potential for sumifilam to become a transformative treatment for patients with Alzheimer disease.

Satralizumab Reduces Risk of Relapse, Including in Treatment-Naïve NMOSD

September 17, 2020

Two posters presented at MDS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.

THN102 Is Safe, Improves Excessive Daytime Sleepiness in Parkinson Disease

September 16, 2020

The investigational drug consistently increased the proportion of patients no longer suffering from daytime sleepiness during treatment.